Fulvestrant as First-Line Treatment for Advanced Breast Cancer

Article

John F. R. Robertson, MD, discusses overall survival data from the phase II FIRST study, which looked at fulvestrant as first-line therapy for patients with advanced breast cancer.

Clinical Pearls

John F. R. Robertson, MD, professor of surgery, faculty of medicine & health sciences, The University of Nottingham, United Kingdom, discusses overall survival data from the phase II FIRST study, which looked at fulvestrant as first-line therapy for patients with advanced breast cancer.

  • 20-25 years ago, the average survival among patients with advanced breast cancer was 24 months. Now, it is 54.1 months.
  • Overall survival was 5.7 months higher with fulvestrant compared with anastrozole.
  • Benefit for fulvestrant over anastrozole was consistent across subgroups.

<<<

Go back to the SABCS conference page

Related Videos
Video 3 - "Managing Toxicities and Adverse Reactions in HR+/Her2-Low mBC Therapies"
Video 2 - "EMERALD: Underscoring Key Elacestrant Data + Subgroup Analyses for Informed Therapy Selection"
Video 1 - "A 62-Year-Old Woman with HR+ HER2-low Metastatic Breast Cancer and Lung, Liver, and Bone Metastases and Using Biomarker Testing to Guide Treatment Selection"
Related Content